Phase 1 Clinical Trial of Ebola Vaccine Passes Safety Test, Shows Good Immune Response

by Dr. Trupti Shirole on April 7, 2015 at 3:30 PM
Font : A-A+

Phase 1 Clinical Trial of Ebola Vaccine Passes Safety Test, Shows Good Immune Response

The Ebola epidemic has ravaged West Africa for more than a year now. Researchers are working on finding an effective vaccine against the deadly Ebola virus. A new study claimed that an experimental Ebola vaccine called VSV-EBOV appears safe and generates immune response in a small phase 1 clinical trial.

Scientists at the Public Health Agency of Canada's National Microbiology Laboratory originally developed the VSV-EBOV vaccine. The vaccine does not contain Ebola virus and cannot cause Ebola virus disease.


Two independent but coordinated studies, performed at the Walter Reed Army Institute of Research (WRAIR) and the National Institute of Allergy and Infectious Diseases (NIAID), explored the safety and immunogenicity of the Ebola vaccine when administered at different dosages. Lt. Col. Jason Regules, co-lead author of the study said, "These pivotal early studies helped inform dose selection for testing of VSV-EBOV vaccine in a large-scale clinical trial in West Africa. We were gratified to see that the vaccine was not associated with significant adverse effects in this very carefully monitored study."

During the trials, researchers collectively enrolled 52 volunteers who received either the vaccine candidate or a placebo. Volunteers who were given the vaccine received one of two different doses and volunteers were assessed on days 1, 3, 7, 14, and 28 to see if they developed anti-Ebola antibodies. The researchers found that 26 of 28 volunteers in the vaccine group showed the intended Ebola glycoprotein antibody response within two weeks of vaccination, and all of the volunteers had antibodies within 28 days of receiving the vaccine. Researchers saw a higher antibody response in the vaccine recipients who received the higher vaccine dose.

Col. Stephen Thomas, senior author of the study, said, "Researchers saw a robust immune response following a single dose of the vaccine, which could be particularly useful in outbreak interventions. We were able to leverage the WRAIR's experience in conducting ethical and safe clinical research experiments to meet a global need."

The study has been published in the New England Journal of Medicine.

Source: Medindia

News A-Z
News Category
What's New on Medindia
World Alzheimer's Day 2021 - 'Know Dementia, Know Alzheimer's
'Hybrid Immunity' may Help Elude COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Clinical Trials Clinical Trials - The Past and The Future Clinical Trials - Different Phases of the trial Myasthenia Gravis Placebo Effects: Rare Insights Congo Fever Vaccination for Children Ebola Virus Disease Top 10 Vaccine Myths Debunked 

Recommended Reading
Ebola Virus Disease
Ebola is caused by a virus via direct contact with body fluids or infected blood. Scientists have .....
World Support for Ebola: US$35 Million Funding from King Abdallah of Saudi Arabia
Zaire ebolavirus is commonly known as Ebola. It was previously known as ebola haemorrhagic fever ......
Ontario Patient With Symptoms of Ebola Tests Negative at Sunnybrook
The patient had returned to Canada from West Africa 10 days earlier and was put into isolation as a ...
Liberia Reports First Ebola Infection After a Month
After suffering over 4,000 deaths due to the deadly virus, Liberia was supposed to be declared ......
Clinical Trials
Clinical trials are experiments that yield useful information to clinicians if a particular treatmen...
Clinical Trials - Different Phases of the trial
Clinical trials serve as a vital component for improving the treatment of medical conditions as they...
Clinical Trials - The Past and The Future
Many of the drugs that are used today have been discovered by chance or often by mere serendipity...
Congo Fever
Crimean-Congo Hemorrhagic fever (CCHF) is a viral disease that affects people who are bitten by infe...
Myasthenia Gravis
Myasthenia gravis is the commonest disorder of neuromuscular transmission. Autoimmune myasthenia gra...
Placebo Effects: Rare Insights
Placebo response is now generally well accepted. ‘Placebo response’ is the friend of the clinician a...
Top 10 Vaccine Myths Debunked
Childhood vaccination has saved many lives, yet lots more has to be done to increase awareness and e...
Vaccination for Children
Vaccines are biological products that impart immunity to the recipient. Vaccines may be live attenua...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use